Jean Donadieu

List of Publications by Year
in descending order

128 papers	12,037 citations	30070 54 h-index	27406 106 g-index
134 all docs	134 docs citations	134 times ranked	10294 citing authors

#	Article	IF	Citations
1	Heterozygous variants of CLPB are a cause of severe congenital neutropenia. Blood, 2022, 139, 779-791.	1.4	25
2	ALK-positiveÂhistiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood, 2022, 139, 256-280.	1.4	60
3	Establishment of MOS-SF36 percentile ranks in the general youth French population. BMC Psychology, 2022, 10, 74.	2.1	2
4	Prognostic impact of pulmonary nodules diagnosed at initial presentation in patients with osteosarcoma. Pediatric Blood and Cancer, 2022, , e29725.	1.5	1
5	Eye movement abnormalities in neurodegenerative langerhans cell histiocytosis. Neurological Sciences, 2022, 43, 6539-6546.	1.9	3
6	Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients. European Journal of Cancer, 2022, 172, 138-145.	2.8	15
7	Identification of biallelic germline variants of SRP68 in a sporadic case with severe congenital neutropenia. Haematologica, 2021, 106, 1216-1219.	3.5	10
8	High frequency of clonal hematopoiesis in Erdheim-Chester disease. Blood, 2021, 137, 485-492.	1.4	30
9	Langerhans cell histiocytosis with extensive lung destruction: Not always the worstâ€case scenario. Pediatric Pulmonology, 2021, 56, 327-328.	2.0	0
10	Inherited GATA2 Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical Penetrance. Journal of Clinical Immunology, 2021, 41, 639-657.	3.8	30
11	Long-term outcome of severe paediatric pulmonary Langerhans cell histiocytosis: do not underestimate lung plasticity. BMJ Case Reports, 2021, 14, e241860.	0.5	1
12	ShwachmanâĐiamond syndrome and solid tumors: Three new patients from the French Registry for Severe Chronic Neutropenia and literature review. Pediatric Blood and Cancer, 2021, 68, e29071.	1.5	4
13	CXCR4 signaling controls dendritic cell location and activation at steady state and in inflammation. Blood, 2021, 137, 2770-2784.	1.4	16
14	Cutaneous adverse events in children treated with vemurafenib for refractory BRAF^{V600E} mutated Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2021, 68, e29140.	1.5	6
15	A circulating subset of BRAF^{V600E}â€positive cells in infants with highâ€risk Langerhans cell histiocytosis treated with BRAF inhibitors. British Journal of Haematology, 2021, 194, 745-749.	2.5	5
16	Histiocytosis. Lancet, The, 2021, 398, 157-170.	13.7	58
17	Somatic genetic rescue of a germline ribosome assembly defect. Nature Communications, 2021, 12, 5044.	12.8	44
18	Recurrent bacterial infections, but not fungal infections, characterise patients with ELANEâ€related neutropenia: a French Severe Chronic Neutropenia Registry study. British Journal of Haematology, 2021, 194, 908-920.	2.5	11

#	Article	IF	Citations
19	Chronic neutropenia: how best to assess severity and approach management?. Expert Review of Hematology, 2021, 14, 945-960.	2.2	6
20	Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis. Journal of Pediatrics, 2021, 237, 65-70.e3.	1.8	8
21	Postâ€COVIDâ€19 severe neutropenia. Pediatric Blood and Cancer, 2021, 68, e28866.	1.5	9
22	EFL1 deficiency: a little is better than nothing. Blood, 2021, 138, 2016-2018.	1.4	0
23	Congenital and Acquired Chronic Neutropenias: Challenges, Perspectives and Implementation of the EuNetâ€INNOCHRON Action. HemaSphere, 2020, 4, e406.	2.7	2
24	Longâ€term followâ€up of children with risk organâ€negative Langerhans cell histiocytosis after 2â€chlorodeoxyadenosine treatment. British Journal of Haematology, 2020, 191, 825-834.	2.5	14
25	Chest computed tomography findings for a cohort of children with pulmonary Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2020, 67, e28496.	1.5	7
26	Central nervous system involvement in Erdheim-Chester disease. Neurology, 2020, 95, e2746-e2754.	1.1	22
27	Childhood Langerhans cell histiocytosis with severe lung involvement: a nationwide cohort study. Orphanet Journal of Rare Diseases, 2020, 15, 241.	2.7	14
28	Longâ€term efficacy and safety of 2CdA (cladribine) in extraâ€pulmonary adultâ€onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review. British Journal of Haematology, 2020, 189, 869-878.	2.5	14
29	PTPN11 mutations in canine and human disseminated histiocytic sarcoma. International Journal of Cancer, 2020, 147, 1657-1665.	5.1	14
30	HSCT may lower leukemia risk in ELANE neutropenia: a beforeâ€“after study from the French Severe Congenital Neutropenia Registry. Bone Marrow Transplantation, 2020, 55, 1614-1622.	2.4	24
31	Infectious and digestive complications in glycogen storage disease type Ib: Study of a French cohort. Molecular Genetics and Metabolism Reports, 2020, 23, 100581.	1.1	12
32	How Many Patients Have Congenital Neutropenia? a Population-Based Estimation from the Nationwide French Severe Chronic Neutropenia Registry. Blood, 2020, 136, 40-41.	1.4	3
33	Diabetes Mellitus, Extreme Insulin Resistance, and Hypothalamic-Pituitary Langerhans Cells Histiocytosis. Case Reports in Endocrinology, 2019, 2019, 1-8.	0.4	1
34	Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. Journal of Clinical Oncology, 2019, 37, 2857-2865.	1.6	132
35	Atteintes ostÃ©oarticulaires au cours des histiocytoses. Revue Du Rhumatisme Monographies, 2019, 86, 120-125.	0.0	0
36	Management of Gorham Stout disease with skull-base defects: Case series of six children and literature review. International Journal of Pediatric Otorhinolaryngology, 2019, 124, 152-156.	1.0	14

#	Article	IF	Citations
37	EFL1 mutations impair eIF6 release to cause Shwachman-Diamond syndrome. Blood, 2019, 134, 277-290.	1.4	48
38	Childhood pulmonary Langerhans cell histiocytosis: a comprehensive clinical-histopathological and BRAFV600E mutation study from the French national cohort. Human Pathology, 2019, 89, 51-61.	2.0	14
39	Severe Transitory Neonatal Neutropenia Associated with Maternal Autoimmune or Idiopathic Neutropenia. Journal of Clinical Immunology, 2019, 39, 200-206.	3.8	3
40	Cladribineâ€related immunosuppression may have fostered graftâ€versusâ€host disease after lung transplant for pulmonary Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2019, 66, e27477.	1.5	4
41	Highly sensitive methods are required to detect mutations in histiocytoses. Haematologica, 2019, 104, e97-e99.	3.5	27
42	Phenotypes and survival in Erdheimâ€Chester disease: Results from a 165â€patient cohort. American Journal of Hematology, 2018, 93, E114-E117.	4.1	94
43	TP53 mutations: the dawn of Shwachman clones. Blood, 2018, 131, 376-377.	1.4	8
44	Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood, 2018, 131, 2877-2890.	1.4	335
45	Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. British Journal of Haematology, 2018, 183, 608-617.	2.5	54
46	Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamondâ€“like syndrome. Blood, 2018, 132, 1318-1331.	1.4	85
47	Distinctive vasculopathy with systemic involvement due to levamisole long-term therapy: aÂcase report. Journal of Medical Case Reports, 2018, 12, 209.	0.8	6
48	Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. Haematologica, 2018, 103, 1278-1287.	3.5	129
49	Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncology, The, 2017, 18, e113-e125.	10.7	154
50	Circulating cellâ€free BRAF^{V600E} as a biomarker in children with Langerhans cell histiocytosis. British Journal of Haematology, 2017, 178, 457-467.	2.5	57
51	Lymphoid differentiation of hematopoietic stem cells requires efficient Cxcr4 desensitization. Journal of Experimental Medicine, 2017, 214, 2023-2040.	8.5	36
52	Neurodegeneration in histiocytoses might start in utero. Lancet Neurology, The, 2017, 16, 953-954.	10.2	2
53	Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history. British Journal of Haematology, 2017, 179, 557-574.	2.5	115
54	How to differentiate congenital from noncongenital chronic neutropenia at the first medical examination? Proposal of score: A pilot study from the French Severe Chronic Neutropenia registry. Pediatric Blood and Cancer, 2017, 64, e26722.	1.5	17

#	Article	IF	Citations
55	Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study. Orphanet Journal of Rare Diseases, 2017, 12, 95.	2.7	57
56	Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood, 2017, 130, 1377-1380.	1.4	146
57	Application of wholeâ€exome sequencing to unravel the molecular basis of undiagnosed syndromic congenital neutropenia with intellectual disability. American Journal of Medical Genetics, Part A, 2017, 173, 62-71.	1.2	23
58	New somatic BRAF splicing mutation in Langerhans cell histiocytosis. Molecular Cancer, 2017, 16, 115.	19.2	37
59	BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. Journal of Clinical Oncology, 2016, 34, 3023-3030.	1.6	233
60	Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30â€year nationwide cohort of 1478 patients under 18Âyears of age. British Journal of Haematology, 2016, 174, 887-898.	2.5	83
61	Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood, 2016, 127, 2672-2681.	1.4	1,040
62	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	9.4	372
63	Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis. Blood, 2015, 125, 2448-2449.	1.4	28
64	Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. Blood, 2015, 126, 1885-1892.	1.4	76
65	Severe chronic primary neutropenia in adults: report on a series of 108 patients. Blood, 2015, 126, 1643-1650.	1.4	32
66	Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood, 2015, 126, 1415-1423.	1.4	117
67	Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAF^{V600E}-Mutated Erdheim-Chester Disease. Journal of Clinical Oncology, 2015, 33, 411-418.	1.6	238
68	Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis. Journal of the American Academy of Dermatology, 2015, 73, e29-e30.	1.2	22
69	Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. JAMA Oncology, 2015, 1, 836.	7.1	92
70	Cladribine improves lung cysts and pulmonary function in a child with histiocytosis. European Respiratory Journal, 2015, 45, 831-833.	6.7	20
71	Early-onset hypogammaglobulinemia: A survey of 44 patients. Journal of Allergy and Clinical Immunology, 2015, 136, 1097-1099.e2.	2.9	5
72	Langerhans cell histiocytosis in children: Correlation of BRAF status with clinical characteristic.. Journal of Clinical Oncology, 2015, 33, 10003-10003.	1.6	0

#	Article	IF	Citations
73	Clinical spectrum and long-term follow-up of 14 cases with G6PC3 mutations from the French severe congenital neutropenia registry. Orphanet Journal of Rare Diseases, 2014, 9, 183.	2.7	48
74	Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology, 2014, 83, 1478-1480.	1.1	70
75	Neurological findings and genetic alterations in patients with Kostmann syndrome and HAX1 mutations. Pediatric Blood and Cancer, 2014, 61, 1041-1048.	1.5	24
76	JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropenia. Nature Genetics, 2014, 46, 1021-1027.	21.4	119
77	Prevention of Infections During Primary Immunodeficiency. Clinical Infectious Diseases, 2014, 59, 1462-1470.	5.8	81
78	The cognitive spectrum in neurodegenerative Langerhans cell histiocytosis. Journal of Neurology, 2014, 261, 1537-1543.	3.6	13
79	Cohen syndrome is associated with major glycosylation defects. Human Molecular Genetics, 2014, 23, 2391-2399.	2.9	79
80	Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. Blood, 2014, 123, 2229-2237.	1.4	135
81	Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood, 2014, 124, 3016-3019.	1.4	197
82	Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood, 2014, 124, 1119-1126.	1.4	208
83	Natural history of Barth syndrome: a national cohort study of 22 patients. Orphanet Journal of Rare Diseases, 2013, 8, 70.	2.7	93
84	Epidemiology of Congenital Neutropenia. Hematology/Oncology Clinics of North America, 2013, 27, 1-17.	2.2	55
85	Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical workâ€up, and treatment for patients till the age of 18 years. Pediatric Blood and Cancer, 2013, 60, 175-184.	1.5	496
86	Cardiomyopathies and congenital heart diseases in Shwachmanâ€“Diamond syndrome: A national survey. International Journal of Cardiology, 2013, 167, 1048-1050.	1.7	13
87	Thymus and mediastinal node involvement in childhood langerhans cell histiocytosis: Longâ€term followâ€up from the French national cohort. Pediatric Blood and Cancer, 2013, 60, 1759-1765.	1.5	35
88	High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. Blood, 2013, 121, 822-829.	1.4	189
89	Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood, 2013, 121, 5006-5014.	1.4	343
90	Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood, 2013, 121, 1495-1500.	1.4	479

#	Article	IF	Citations
91	Classification of and risk factors for hematologic complications in a French national cohort of 102 patients with Shwachman-Diamond syndrome. Haematologica, 2012, 97, 1312-1319.	3.5	120
92	High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood, 2012, 120, 2700-2703.	1.4	589
93	Tetralogy of Fallot is an Uncommon Manifestation of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome. Journal of Pediatrics, 2012, 161, 763-765.	1.8	37
94	B cellâ€“helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nature Immunology, 2012, 13, 170-180.	14.5	615
95	Medical management of langerhans cell histiocytosis from diagnosis to treatment. Expert Opinion on Pharmacotherapy, 2012, 13, 1309-1322.	1.8	86
96	Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet Journal of Rare Diseases, 2012, 7, 71.	2.7	96
97	B-RAF Mutant Alleles Associated with Langerhans Cell Histiocytosis, a Granulomatous Pediatric Disease. PLoS ONE, 2012, 7, e33891.	2.5	132
98	Neutrophil depletion impairs natural killer cell maturation, function, and homeostasis. Journal of Experimental Medicine, 2012, 209, 565-580.	8.5	199
99	Extended Spectrum of Human Glucose-6-Phosphatase Catalytic Subunit 3 Deficiency: Novel Genotypes and Phenotypic Variability in Severe Congenital Neutropenia. Journal of Pediatrics, 2012, 160, 679-683.e2.	1.8	67
100	Draft consensus guidelines for diagnosis and treatment of Shwachmanâ€Diamond syndrome. Annals of the New York Academy of Sciences, 2011, 1242, 40-55.	3.8	183
101	Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study. Orphanet Journal of Rare Diseases, 2011, 6, 83.	2.7	48
102	Congenital neutropenia: diagnosis, molecular bases and patient management. Orphanet Journal of Rare Diseases, 2011, 6, 26.	2.7	173
103	Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman-Diamond syndrome. Genes and Development, 2011, 25, 917-929.	5.9	247
104	Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica, 2010, 95, 1534-1541.	3.5	176
105	Is pegfilgrastim safe and effective in congenital neutropenia? An analysis of the French Severe Chronic Neutropenia registry. Pediatric Blood and Cancer, 2009, 53, 1068-1073.	1.5	24
106	2â€²â€chlorodeoxyadenosine (2â€CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCHâ€Šâ€98 protocol of the histiocyte society. Pediatric Blood and Cancer, 2009, 53, 1271-1276.	1.5	97
107	Cholesteatoma Secondary to Temporal Bone Involvement by Langerhans Cell Histiocytosis. Otology and Neurotology, 2009, 30, 190-193.	1.3	11
108	Respiratory distress and sudden death of a patient with GSDIb chronic neutropenia: possible role of pegfilgrastim. Haematologica, 2009, 94, 1175-1177.	3.5	13

#	Article	IF	Citations
109	Neutropenia in congenital nephrotic syndrome of the Finnish type: role of urinary ceruloplasmin loss. Blood, 2009, 113, 4820-4821.	1.4	16
110	18F-FDG PET in neurodegenerative Langerhans cell histiocytosis. Journal of Neurology, 2008, 255, 575-580.	3.6	30
111	Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000â€“2004. Pediatric Blood and Cancer, 2008, 51, 71-75.	1.5	248
112	Reactivations in Multisystem Langerhans Cell Histiocytosis: Data of the International LCH Registry. Journal of Pediatrics, 2008, 153, 700-705.e2.	1.8	88
113	Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood, 2008, 111, 2556-2562.	1.4	287
114	Herpes-Virus Infection in Patients with Langerhans Cell Histiocytosis: A Case-Controlled Sero-Epidemiological Study, and In Situ Analysis. PLoS ONE, 2008, 3, e3262.	2.5	48
115	Estimation of the Radiation Dose From Thoracic CT Scans in a Cystic Fibrosis Population. Chest, 2007, 132, 1233-1238.	0.8	46
116	Epigenetic Regulation of Protein-Coding and MicroRNA Genes by the Gfi1-Interacting Tumor Suppressor PRDM5. Molecular and Cellular Biology, 2007, 27, 6889-6902.	2.3	79
117	Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood, 2007, 110, 1648-1655.	1.4	88
118	Is G-CSF-mobilized peripheral stem cell harvest harmful?. Pediatric Blood and Cancer, 2007, 48, 595-595.	1.5	3
119	The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report. Supportive Cancer Therapy, 2006, 3, 220-231.	0.3	135
120	Langerhans cell histiocytosis: a clinical update. , 2005, , 95-129.		30
121	Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica, 2005, 90, 45-53.	3.5	234
122	Incidence of Growth Hormone Deficiency in Pediatric-Onset Langerhans Cell Histiocytosis: Efficacy and Safety of Growth Hormone Treatment. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 604-609.	3.6	95
123	A New clinical score for disease activity in Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2004, 43, 770-776.	1.5	82
124	Endocrine involvement in pediatric-onset langerhans' cell histiocytosis: a population-based study. Journal of Pediatrics, 2004, 144, 344-350.	1.8	181
125	Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood, 2004, 103, 4119-4125.	1.4	187
126	Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor. Seminars in Hematology, 2002, 39, 134-140.	3.4	54

#	Article	IF	Citations
127	Langerhans Cell Histiocytosis and the Central Nervous System in Childhood: Evolution and Prognostic Factors. Results of a Collaborative Study. Journal of Child Neurology, 2000, 15, 150-156.	1.4	63
128	Renal Carcinoma in a Patient With Glycogen Storage Disease Ib Receiving Long-term Granulocyte Colony-Stimulating Factor Therapy. The American Journal of Pediatric Hematology/oncology, 2000, 22, 188-189.	1.3	12